Parabilis Medicines priced its initial public offering at $770.5 million, the largest capital raise for a genomics-focused company since AbCellera's $555 million debut in December 2021. The company sold 38.5 million shares at $20 per share, the top of its revised range, according to filings reviewed Thursday morning. Underwriters have a standard 30-day greenshoe option for an additional 5.8 million shares, which could push total proceeds past $886 million.
The pricing came without warning. Parabilis had quietly amended its S-1 on Monday, raising the proposed range from $16-$18 to $19-$21 after what sources describe as oversubscription from life sciences-focused crossover funds. Lead bookrunners Goldman Sachs and Morgan Stanley allocated roughly 62% of the offering to long-only institutional accounts, with the remainder split between healthcare-specialist hedge funds and a small tranche reserved for strategic corporate investors. Trading begins Friday on Nasdaq under ticker PARA.
The deal matters because it reopens a window that's been nailed shut. Biotech IPOs raised just $3.2 billion in 2023, down 74% from the $12.4 billion raised in 2021, per Renaissance Capital. Parabilis is the first genomics platform to clear $500 million in nearly two years, and the first to price above range in that category since the Fed began tightening. The company's pre-money valuation of approximately $2.8 billion values it at 14x its last private round in June 2023, when it raised $180 million at a $200 million post-money from Arch Venture Partners and a16z Bio. That multiple compression from private to public—common in 2021—has been absent in recent biotech listings, most of which priced flat or down.
Parabilis develops gene-editing platforms for rare metabolic disorders, with three programs in Phase 1 and a disclosed pipeline targeting 12 genetic conditions with fewer than 50,000 diagnosed patients globally. The company has no revenue, burned $142 million in the twelve months ending September 2024, and projects a cash runway extending into Q3 2027 with the new capital. What it does have: exclusive licensing agreements with two top-ten pharma companies for undisclosed indications, and a platform that cuts CRISPR editing time from 72 hours to under 6 hours in preclinical models, per its S-1.
Allocators should track three follow-on events. First, whether the stock holds its IPO price through the 180-day lockup expiration in late May 2025—a test of whether this capital is patient or simply rotating out of illiquid VC positions. Second, Parabilis is expected to release interim Phase 1 data for its lead program, PBM-101, in Q2 2025; that readout will set the valuation framework for the next wave of gene-editing companies considering public markets. Third, watch for amendments to the two undisclosed pharma partnerships, which account for $420 million in potential milestones but no upfront economics—a structure that suggests the partnerships were struck before this IPO momentum materialized.
The pricing also clarifies what kind of biotech can still access growth capital. Parabilis is not a platform play with Nobel-adjacent science and a vague development timeline. It has defined programs, binary clinical catalysts within 18 months, and a management team that includes former Biogen and Vertex executives who've taken drugs through FDA approval. The market is buying execution risk, not concept risk. That's the line.